We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current MEDCL market cap is 400.02M. The company's latest EPS is EUR -0.8613 and P/E is -15.98.
| Year End March 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 6M | 11.83M | 8.55M | 14.38M | 12.29M |
| Operating Income | -19.33M | -15.37M | -23.7M | -24.05M | -20.83M |
| Net Income | -23.92M | -19.02M | -24.81M | -32.01M | -25.04M |
| Year End March 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 27.31M | 63.61M | 44.3M | 29.34M | 36.95M |
| Total Liabilities | 43.27M | 54.69M | 57.67M | 71.63M | 77.77M |
| Total Equity | -15.96M | 8.92M | -13.37M | -42.29M | -40.82M |
| Year End March 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | -12.54M | -12.14M | -21.36M | -21.01M | -11.92M |
| Investing | 72k | -1.06M | -316k | 1.3M | -613k |
| Financing | 3.56M | 47.92M | -800k | 1.56M | 25.53M |
| Market Cap | 400.02M |
| Price to Earnings Ratio | -15.98 |
| Price to Sales Ratio | 32.55 |
| Price to Cash Ratio | 20.56 |
| Price to Book Ratio | -9.8 |
| Dividend Yield | - |
| Shares Outstanding | 29.07M |
| Average Volume (1 week) | 53.38k |
| Average Volume (1 Month) | 94.79k |
| 52 Week Change | 44.84% |
| 52 Week High | 19.00 |
| 52 Week Low | 9.05 |
| Spread (Intraday) | 0.28 (2%) |
| Company Name | Medincell SA |
| Address |
3 rue des freres lumiere jacou, occitan 34830 |
| Website | https://www.medincell.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
